

Curriculum Vitae

Date: June 2024

Name: Aaron Solomon Farberg

Professional Address:

Bare Derm Group, Inc
2110 Research Row
Dallas, Texas 75235
November 2022 – Present

Reveal Research Institute, PLLC
2110 Research Row Ste 310B-
Dallas, Texas 75235
November 2022 – Present

12850 Dallas Parkway #300
Frisco, Texas 75033

Education:

2003 – 2006	Emory University Atlanta, Georgia B.S. in Neuroscience – Summa Cum Laude
2008 – 2012	University of Michigan School of Medicine Ann Arbor, Michigan M.D. with highest honors in research
2009 – 2010	Research Fellow, Craniofacial Research Laboratory, Section of Plastic and Reconstructive Surgery, Department of Surgery University of Michigan Health System Ann Arbor, Michigan
2012 – 2015	Resident, Section of Plastic and Reconstructive Surgery, Department of Surgery University of Michigan Health System Ann Arbor, Michigan
2015 – 2016	Research Training Fellow National Society for Cutaneous Medicine New York University Medical Center New York, New York
2016 – 2018	Resident, Department of Dermatology Icahn School of Medicine at Mount Sinai

New York, New York

2018 – 2019
Chief Resident and Assistant Instructor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

2019 – 2020
Advanced Dermatologic Surgery Fellow and
Assistant Instructor
Arkansas Dermatology
Little Rock, Arkansas

Licensure Information:

Arkansas Medical License, # E-11894
New York Medical License, # 280730
Texas Medical License, # S7868

Board Certification:

Dermatology – July 2019
Micrographic Dermatologic Surgery – October 2021

Appointments:

2022 Nov – Present
Chief Medical Officer, Founding Partner
Dermatologist and Micrographic Surgeon
Bare Derm Group, Inc.
Dallas, Texas

2022 Nov – Present
Executive Director, Principal Investigator
Reveal Research Institute, PLLC
Dallas, Texas

2022 Nov – Present
Adjunct Clinical Assistant Professor
Assistant Residency Program Director
Division of Dermatology
Department of Internal Medicine and Geriatrics
UNT Health Science Center
Fort Worth, Texas

2021 Jan – Present
Adjunct Clinical Assistant Professor, Surgeon
Section of Dermatology
Baylor Scott & White Health System
Dallas, Texas

2021 Jan – Present	Adjunct Clinical Assistant Professor Section of Dermatology Texas A&M College of Medicine Dallas, Texas
2020 Jul – Present	President Dermatology Science and Research Foundation 501(c)3 Chicago, Illinois
2019 July – 2020 Nov	Adjunct Clinical Instructor Department of Dermatology Icahn School of Medicine at Mount Sinai New York, New York
2020 Jan – 2020 Aug	Director Arkansas Research Trials, LLC North Little Rock, Arkansas
2019 July – 2020 Aug	Dermatologist and Mohs Surgeon Arkansas Dermatology and Skin Cancer Center Little Rock, Arkansas
2019 July – 2020 July	Assistant Clinical Professor Department of Dermatology Arkansas College of Osteopathic Medicine Fort Smith, Arkansas

Memberships in Professional Organizations:

American Academy of Dermatology
 American Society for Dermatologic Surgery
 International Society of Dermatology
 American Medical Association
 Women’s Dermatologic Society
 National Society for Cutaneous Medicine
 American Society for Laser Medicine & Surgery
 Texas Medical Society

Texas Dermatology Society

Dallas Society of Dermatology

Committee Memberships

2005 – 2006	Chair, Philanthropy Committee Alpha Epsilon Pi Fraternity, Epsilon Chapter Emory University
2006 – 2007	Member, Academic Standards Faculty Standing Committee Emory University
2009 – 2010	Member, Pediatric Ethics Committee University of Michigan Health System
2011 – 2012	Melanoma Chair National Dermatology Interest Group Association
2013 – 2014	Member, Adult Ethics Committee University of Michigan Health System
2014 – 2015	Member, OR Advisory Board University of Michigan Health System
2015 – 2018	Resident Representative, New York Legislative Conference American Academy of Dermatology Association
2016	Faculty Reviewer, Real World Dermatology Conference for NP/PA's National Society for Cutaneous Medicine
2016 – 2019	Resident Board Member, New York State Society of Dermatology and Dermatological Surgery
2017 – 2019	Resident Liaison, American Society for Dermatologic Surgery
2018 – 2020	Chair, Resident Workgroup, SkinPAC American Academy of Dermatology Association
2018 – 2020	Resident Member, Mohs Micrographic Surgery Committee, American Academy of Dermatology

2019 – Present	State Representative Alternate Dermatology Medicare Carrier Advisory Committee American Academy of Dermatology Association
2020 – Present	Board Member, SkinPAC American Academy of Dermatology Association
2021 – Present	Director, LEAD Initiative Foundation for Research and Education in Dermatology
2022 – Present	Board Member, Early Career Initiative Foundation for Research and Education in Dermatology
2022 – Present	Board Member, Leadership Committee American Academy of Dermatology Association
2022 – Present	Faculty Member Galderma International Sensitive Skin Care Program
2022 – Present	Deputy Chair Dermatology Medicare Carrier Advisory Committee American Academy of Dermatology Association
2024 – Present	Board Member Clinical Guidelines Committee American Academy of Dermatology

Honors:

2005	Sam Bredow Memorial Scholarship Emory University
2005	Sigma Xi
2005 – 2006	Dean’s List Emory University

2006	Grant Award, Scholarly Inquiry and Research Emory University
2007	First Place, Atlanta Chapter of the Society for Neuroscience Poster Preview
2009	Grant Award, Fostering Innovation Award University of Michigan Health System
2009	Summer Biomedical Research Grant Recipient and Travel Award University of Michigan Health System
2009	Research Grant Award American Society of Maxillofacial Surgeons
2009	Inside Scoop Featured Article, Fall Medicine at Michigan Magazine
2010	Research Grant Award American Society of Maxillofacial Surgeons
2010	Excellence in Research, Moses Gunn Research Conference, Department of Surgery University of Michigan Health System
2010	First Place, Innovations Poster Competition Society of Hospital Medicine
2010 – 2012	Academic Scholar, Jewish Federation of Metropolitan Chicago
2011 – 2012	Sheldon E. Cohen Merit Scholarship University of Michigan Medical School
2014	Grant Award, Fostering Innovation Award University of Michigan Health System
2015 – 2016	Project Award, Coulter Translational Research Partnership Program, University of Michigan
2016 – 2019	First Place, Resident Research Competition Winter Clinical Dermatology Conference
2017	First Place, Graduate Medical Education Research Day Abstract Competition

Icahn School of Medicine at Mount Sinai

- | | |
|------------------|--|
| 2018 – 2019 | Member Selection, Doctors Reaching for Excellence in Aesthetic Medicine
South Beach Symposium, Miami FL |
| 2019 | Second Place, Dermatologic Society of Greater New York. Annual Resident Research Competition |
| 2019 | Second Place, New York Academy of Medicine, Dermatology Residents' Night |
| 2019, 2020, 2022 | Stars of the Academy
American Academy of Dermatology |
| 2023 | NEWSWEEK Magazine
#1 Dermatologist in Texas
#5 Dermatologist in USA
Anonymous vote of 2000+ dermatology peers |

Related Medical Experience:

- | | |
|----------------|--|
| 2015 – 2019 | Consultant Dermatologist
New York Yankees |
| 2016 – 2017 | Medical Consultant
InvisiShade |
| 2017 | Medical Consultant
BMHS Investments |
| 2018 – 2019 | Consultant Dermatologist
Educational Resource Systems, Inc. |
| 2019 – Present | Consultant Dermatologist
HealthCentral online |
| 2020 – Present | Medical Director Consultant
Castle Biosciences Inc. |
| 2020 – Present | Medical Advisor
Gore Range Capital Investment Fund |
| 2021 – Present | Chief Medical Advisor
Clear Health |

2022 – Present Board Director, Medical Advisor
SurgiVance

2023 – Present Medical Board, Member
Editor-in-Chief 2024
Dermatology Times

Editorial Boards:

2016 – present SKIN: The Journal for Cutaneous Medicine,
Founding Member, Editorial Board

2018 – present International Journal of Cancer, Reviewer

2019 – present Journal of the American Academy of Dermatology,
Reviewer

2019 – present Australasian Journal of Dermatology, Reviewer

2019 – present Photodermatology, Photoimmunology &
Photomedicine, Reviewer

2020 – present British Journal of Dermatology, Reviewer

2020 – present Preventive Medicine, Reviewer

2020 – present Journal of The European Academy of Dermatology
and Venereology, Reviewer

2022 – present Dermatology and Therapy, Editorial Board Member

2022 – present Current Oncology, Reviewer

Funded Research:

PI: Dear Doctor... Notes. Fostering Innovation Grant, Office of CEO, University of Michigan Health System. 2009.

PI: Angiogenic Effect of Deferoxamine on Irradiated Mandible in Distraction Osteogenesis. American Society of Maxillofacial Surgeons & Synthes CMF Research Grant Award. 2009.

PI: Amifostine and Deferoxamine Combination Therapy in Irradiated Mandibular Distraction Osteogenesis. American Society of Maxillofacial Surgeons & Synthes CMF Research Grant Award. 2010.

PI: Tissue-MATE expander device project Fostering Innovation Grant, Office of CEO, University of Michigan Health System. 2014.

PI: Device to Aid in Arterial Microanastomosis. Coulter Translational Research Partnership Program. 2015-2016.

PI: Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Management Decisions. Castle Biosciences Inc. 2016.

Co-PI: Dermatologists' Sunscreen Opinions. Johnson & Johnson Consumer Inc. 2016.

Co-PI: A Single Center, Randomized, Split-Face, Double-Blinded, Single Sun Exposure Evaluation of Sunscreens of SPF 50+ and Above Under Actual Use Conditions. CO-1511 1213 2858-SACT. Johnson & Johnson Consumer Inc. 2015-2016.

Sub-I: The Role of Prophylactic Botulinum Toxin in a Post-Excisional Scars. Allergan. 2016-2018.

Sub-I: Post Excision Fractional CO2 Resurfacing: A Quantitative and Qualitative Scar Analysis. Luminis. 2016-2018.

PI: Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma. CBI_cSCC. Castle Biosciences Inc. 2017-2018.

PI: An investigator-initiated study to evaluate the efficacy, safety, and tolerability of a single application of Jessner's solution and 35% trichloroacetic acid peel in subjects with actinic keratosis. Delasco. 2017-2019.

PI: The Use of Platelet Rich Plasma in Male Androgenic Alopecia. Eclipse Aesthetics. 2018-2019.

Sub-I: LPS15497: Dupilumab effect on Sleep in AD patients; A randomized double-blind placebo-controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis. Phase 4. Sponsor: Sanofi. 2020.

PI: Protocol M18-891: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate dupilumab in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Phase 3. Sponsor: Dermira. 2020

PI: Protocol M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Phase 3. Sponsor: Abbvie. 2020

PI: Protocol M16-047: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Phase 3. Sponsor: Abbvie. 2020

PI: Protocol M18-891: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Phase 3. Sponsor: Abbvie. 2020

PI: A Comparative Analysis of Platelet Rich Plasma Composition of Six Commercial Separation Systems for Androgenetic Alopecia. Eclipse Aesthetics. 2021-2022.

PI: Protocol GU.04.US.SL.017: Assessment of Healing Ointment after dermatologic procedures. Galderma. 2022.

Sub-I: Protocol RPT193-02 RAPT A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis. Therapeutics, Inc. 2023

PI: Protocol CNTO1959PSO3017: A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Guselkumab Versus Placebo for the Treatment of Low BSA Moderate Plaque Psoriasis with Special Site Involvement. Janssen 2023

PI: Protocol CBI_2020_cSCC_CU_001: Clinical Utility and Health Outcomes Study of the DecisionDx®-SCC Prognostic Gene Expression Profile Test (UTILISE). Castle Biosciences, Inc. 2023

Sub-I: Protocol ANB032-201: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis. AnaptysBio, Inc. 2023

Sub-I: Protocol M23-716: A Phase 3, Randomized, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Severe Alopecia. AbbVie. 2023

Sub-I: Protocol PS0021: A Double-Blind, Active-Controlled, Randomized Study to Evaluate the Efficacy and Safety of Bimekizumab in Children and Adolescents with Moderate to Severe Plaque Psoriasis (BE TOGETHER). UCB. 2024

PI: Protocol EFC17599: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 3-Arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection to Participants Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis (AD) Who Are On Background Topical Corticosteroids and Have Had An Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment. Sanofi 2024.

PI: Protocol APG777-201: A Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-To-Severe Atopic Dermatitis. Apogee 2024

PI: Protocol INCB 18424-312: A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants with Nonsegmental Vitiligo. Incyte 2024.

PI: CorEvitas Adolescent AD Registry. 2024

PI: CorEvitas Generalized Pustular Psoriasis Registry. 2024

Sub I: Protocol M20-465 A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa. Abbvie 2024.

Sub I: Protocol CUV105. Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-UVB Light Alone in the Treatment of Vitiligo. Clinuvel 2024.

Patents:

US2016/50037 Device to Aid in Arterial Microvascular Anastomosis

Publications:

1. Farberg AS, Rosen RF, Long PM, Gearing M, Klein W, Walker LC: The posterior cingulate cortex in aging and Alzheimer's disease. Emory University Program in Neuroscience and Behavioral Biology. Honors QP1.5.F37, 2006.
2. Rosen RF, Farberg AS, Gearing M, Dooyema J, Long PM, Anderson DC, Davis-Turak J, Coppola G, Geschwind DH, Pare J, Duong TQ, Hopkins WD, Preuss TM, Walker LC: Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol. 509(3):259-70, 2008.

3. Donneys A, Tchanque-Fossuo CN, Farberg AS, Jing XL, Deshpande SS, Goldstein SA, Buchman SR: Quantitative Analysis of Vascular Response After Mandibular Fracture Repair Using Micro-Computed Tomography With Vessel Perfusion. *Plast Reconstr Surg.* 127(4):1487-93, 2011.
4. Tchanque-Fossuo CN, Monson LA, Farberg AS, Donneys A, Zehtabzadeh AJ, Razdolsky, ER, Buchman SR: Dose-response effect of human equivalent radiation in the murine mandible. Part I. A histomorphometric assessment. *Plast Reconstr Surg.* 128(1):114-21, 2011.
5. Tchanque-Fossuo CN, Monson LA, Farberg AS, Donneys A, Deshpande SS, Razdolsky ER, Halonen NR, Goldstein SA, Buchman SR: Dose-response effect of human equivalent radiation in the murine mandible. Part II. A biomechanical assessment. *Plast Reconstr Surg.* 128(5):480-487, 2011.
6. Donneys A, Tchanque-Fossuo CN, Farberg AS, Deshpande SS, Buchman SR: Bone regeneration in distraction osteogenesis demonstrates significantly increased vascularity in comparison to fracture repair in the mandible. *J Craniofac Surg.* 23(1):328-32, 2012.
7. Donneys A, Farberg AS, Tchanque-Fossuo CN, Deshpande SS, Buchman SR: Deferoxamine enhances the vascular response of bone regeneration in mandibular distraction osteogenesis. *Plast Reconstr Surg.* 129(4):850-6, 2012.
8. Farberg AS, Jing XL, Monson LA, Tchanque-Fossuo CN, Donneys A, Deshpande SS, Buchman SR: Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. *Bone.* 50(5):1184-7, 2012.
9. Donneys A, Nelson NS, Deshpande SS, Boguslawski MJ, Tchanque-Fossuo CN, Farberg AS, Buchman SR: Quantifying mineralization using bone mineral density distribution in the mandible. *J Craniofac Surg.* 23(5):1502-6, 2012.
10. Tchanque-Fossuo CN, Donneys A, Razdolsky ER, Monson LA, Farberg AS, Deshpande SS, Sarhaddi D, Poushanchi B, Goldstein SA, Buchman SR: Quantitative histologic evidence of amifostine-induced cytoprotection in an irradiated murine model of mandibular distraction osteogenesis. *Plast Reconstr Surg.* 130(6):1199-207, 2012.
11. Jing XL, Farberg AS, Monson LA, Donneys A, Tchanque-Fossuo CN, Buchman SR: Radiomorphometric Quantitative Analysis of Vasculature

Utilizing Micro-CT and Vessel Perfusion in the Murine Mandible.
Craniofacial Trauma and Reconstr. 5(4):223-30, 2012.

12. Donneys A, Deshpande SS, Tchangque-Fossuo CN, Johnson KL, Blough JT, Perosky JE, Kozloff KM, Felice PA, Nelson NS, Farberg AS, Levi B, Buchman SR: Deferoxamine expedites consolidation during mandibular distraction osteogenesis. *Bone*. 55(2):384-90, 2013.
13. Monson LA, Jing XL, Donneys A, Farberg AS, Buchman SR: Dose-response effect of human equivalent radiation in the mandible. *J Craniofac Surg*. 24(5):1593-8, 2013.
14. Farberg AS, Lin AM, Kuhn L, Flanders SA, Kim CS: Dear Doctor: a tool to facilitate patient-centered communication. *J Hosp Med*. 8(10):553-8, 2013.
15. Deshpande SS, Donneys A, Tchanque-Fossuo CN, Farberg AS, Buchman SR: Quantification and characterization of radiation-induced changes to mandibular vascularity using micro-computed tomography. *Ann Plast Surg*. 72(1):100-3, 2014.
16. Farberg AS, Sarhaddi D, Donneys A, Deshpande SS, Buchman SR: Deferoxamine enhances bone regeneration in mandibular distraction osteogenesis. *Plast Reconstr Surg*. 133(3):666-71, 2014.
17. Agarwal S, Kidwell KM, Farberg AS, Kozlow JH, Chung KC, Momoh AO: Immediate reconstruction of the radiated breast: Recent trends contrary to traditional standards. *Ann Surg Oncol*. 22(8):2551-9, 2015.
18. Rosen RF, Tomidokoro Y, Farberg AS, Dooyema J, Ciliax B, Preuss TM, Neubert TA, Ghiso JA, LeVine III HL, Walker LC: Comparative pathobiology of Abeta and the unique susceptibility of humans to Alzheimer's disease. *Neurobiol Aging*. 44:185-196, 2016.
19. Monson LA, Nelson NS, Donneys A, Farberg AS, Tchanque-Fossuo CN, Deshpande SS, Buchman SR: Amifostine treatment mitigates the damaging effects of radiation on distraction osteogenesis in the murine mandible. *Ann Plast Surg*. 77(2):164-8, 2016.
20. Winkelmann RR, Farberg AS, Tucker N, White R, Rigel DS: Enhancement of International Dermatologists' Pigmented Skin Lesion Biopsy Decisions Following Dermoscopy with Subsequent Integration of Multispectral Digital Skin Lesion Analysis. *J Clin Aesthet Dermatol*. 9(7):53-5, 2016.

21. Farberg AS, Donohue S, Rigel DS: Hat-wearing patterns in spectators attending baseball games: a 10-year retrospective comparison. *Cutis*. 98(3):181-184, 2016.
22. Farberg AS, Rigel AC, Rigel DS: Online survey of US dermatologists' sunscreen opinions: Perceptions, recommendation factors, and self-usage. *J Drugs Dermatol*. 15(9):1121-3, 2016.
23. Glazer AM, Winkelmann RR, Farberg AS, Rigel DS: Analysis of Trends in US Melanoma Incidence and Mortality. *JAMA Dermatol*. Dec 21, Epub ahead of print, 2016.
24. Farberg AS, Rigel DS: A comparison of current practice patterns of US dermatologists' vs published guidelines for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 75(6):1193-1197, 2016.
25. Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P: Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. *J Am Acad Dermatol*. 19(16):31168-9, 2017.
26. Farberg AS, Glazer AM, Rigel AC, White R, Rigel DS: Dermatologists' Perceptions, Recommendations, and Use of Sunscreen. *JAMA Dermatol*. 153(1):99-101, 2017.
27. Farberg AS, Donohue S, Farberg AM, Teplitz RW, Rigel DS: Cutaneous Implications of Whole Body Cryotherapy. *SKIN*. 1(1), 2017.
28. Glazer AM, Farberg AS, Winkelmann RR, Rigel DS: Analysis of Trends in Geographic Distribution and Density of US Dermatologists. *JAMA Dermatol*. 154(4):322-5, 2017.
29. Bernstein D, Farberg AS, Khorasani H, Kriegel D: Noninvasive Body Contouring: Literature Review and Summary of Objective Data. *SKIN*. 1(1), 2017.
30. Ou-Yang H, Farberg AS, Rigel DS: Types of Shade Vary in Protection Just Like Sunscreens-Reply. *JAMA Dermatol*. 153(10):1071-1072, 2017.
31. Ou-Yang H, Jiang LI, Meyer K, Wang SQ, Farberg AS, Rigel DS: Sun Protection by Beach Umbrella vs Sunscreen with a High Sun Protection Factor: A Randomized Clinical Trial. *JAMA Dermatol*. 153(3):304-308, 2017.

32. Glazer AM, Farberg AS, Winkelmann RR, Tucker N, Rigel DS: Quantitative ABCD parameters measured by a multispectral digital skin lesion analysis device for evaluation of suspicious pigmented skin lesions strongly correlate with clinical ABCD observations. *Dermatol Online J.* 23(8), 2017.
33. Farberg AS, Winkelmann RR, Tucker N, White R, Rigel DS: The Impact of Quantitative Data Provided by a Multi-Spectral Digital Skin Lesion Analysis Device on Dermatologists' Decisions to Biopsy Pigmented Lesions. *J Clin Aesthet Dermatol.* 10(9):24-26, 2017.
34. Farberg AS, Glazer AM, White R, Rigel DS: Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. *J Drug Dermatol.* 16(5):428-31, 2017.
35. Winkelmann RR, Farberg AS, Glazer AM, Cockerell CJ, Sober AJ, Siegel DM, Leachman SA, High WA, Markowitz O, Berman B, Pariser DM, Goldenberg G, Rosen T, Rigel DS: Integrating Skin Cancer-Related Technologies into Clinical Practice. *Dermatol Clin.* 35(4):565-576, 2017.
36. Farberg AS, Rigel DS. The Importance of Early Recognition of Skin Cancer. *Dermatol Clin.* 35(4):xv-xvi, 2017.
37. Farberg AS, Glazer AM, Winkelmann RR, Rigel DS: Assessing Genetic Expression Profiles in Melanoma Prognosis. *Dermatol Clin.* 35(4):545-550, 2017.
38. Winkelmann RR, Farberg AS, Glazer AM, Rigel DS: Noninvasive Technologies for the Diagnosis of Cutaneous Melanoma. *Dermatol Clin.* 35(4):453-456, 2017.
39. Glazer AM, Rigel DS, Winkelmann RR, Farberg AS: Clinical Diagnosis of Skin Cancer: Enhancing Inspection and Early Recognition. *Dermatol Clin.* 35(4):409-416, 2017.
40. Glazer AM, Farberg AS, Donohue S, Rigel DS: Analysis of Dermatologic Disorders Occurring in Major League Baseball Players. *SKIN.* 1(2), 2017.
41. Ouyang H, Meyer K, Maitra P, Daly S, Svoboda RM, Farberg AS, Rigel DS: Realistic Sunscreen Durability: A Randomized, Double-blinded, Controlled Clinical Study. *J Drugs Dermatol.* 17(1):116-117, 2018.
42. Boddu S, Hashim PW, Nia JK, Horowitz R, Farberg AS, Goldenberg G: Regenerative medicine in cosmetic dermatology. *Cutis.* 101(1):33-36, 2018.

43. Glazer AM, Farberg AS, Svoboda RM, Rigel DS: Comparison of Survey Modality and Response Rate in Dermatologist' Perceptions and Opinions of Sunscreens. *SKIN*. 2(2), 2018.
44. Svoboda RM, Glazer AM, Farberg AS, Rigel DS: Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma. *J Drug Dermatol*. 17(5):544-47, 2018.
45. Williams JD, Maitra P, Atillasoy E, Wu MM, Farberg AS, Rigel DS: SPF 100+ sunscreen is more protective against sunburn than SPF 50+ in actual use: Results of a randomized, double-blind, split-face, natural sunlight exposure clinical trial. *J Am Acad Dermatol*. 78(5):902-910, 2018.
46. Rzepecki AK, Farberg AS, Hashim PW, Goldenberg G: Update on noninvasive body contouring techniques. *Cutis*. 101(4):285-288, 2018.
47. Svoboda RM, Glazer AM, Farberg AS, Cowdrew MCE, Rigel DS: Melanoma Reporting Practices of United States Dermatologists. *Dermatol Surg*. 44(11):1391-1395, 2018.
48. Farberg AS, Glazer AM, Winkelmann RR, Tucker N, White R, Rigel DS: Enhanced melanoma diagnosis with multispectral digital skin lesion analysis. *Cutis*. 101(5):338-340, 2018.
49. Farberg AS, Goldenberg G: New guidelines of care for the management of nonmelanoma skin cancer. *Cutis*. 101(5):319-321, 2018.
50. Soliman YS, Horowitz R, Hashim PW, Nia JK, Farberg AS, Goldenberg G: Update on acne scar treatment. *Cutis*. 102(1):21,25,47,48, 2018.
51. Prado G, Svoboda RM, Teplitz RW, Farberg AS, Rigel DS: Patient knowledge of FDA-mandated sunscreen labeling terminology: A cross-sectional survey. *Photodermatol Photoimmunol Photomed*. 35(3):141-7, 2018.
52. Hashim PW, Nia JK, Zade J, Farberg AS, Goldenberg G: Noninvasive vaginal rejuvenation. *Cutis*. 102(4):243-246, 2018.
53. Torbeck RL, Schwarcz R, Hazan E, Wang JV, Farberg AS, Khorasani H: In Vitro Evaluation of Preinjection Aspiration for Hyaluronic Fillers as Safety Checkpoint. *Dermatol Surg*. 45(7):954-8, 2019.
54. Soliman YS, Hashim PW, Farberg AS, Goldenberg G: The role of diet in preventing photoaging and treating common skin conditions. *Cutis*. 103(3):153-156, 2019.

55. Prado G, Ederle AE, Shahriari SRK, Svoboda RM, Farberg AS, Rigel DS: Online sunscreen purchases: Impact of product characteristics and marketing claims. *Photodermatol Photoimmunol Photomed*. 35(5):339-43, 2019.
56. Lin MJ, Dubin DP, Farberg AS, Khorasani H: Acellular porcine transitional cell matrix xenograft for surgical defects. *Australas J Dermatol*. 60(4):e345-e346, 2019.
57. Dubin DP, Farberg AS, Lin MJ, Khorasani H: Intralesional Deoxycholic Acid as Neoadjuvant Treatment of a Large Lipoma. *Dermatol Surg*. 46(5):715-7.
58. Dubin DP, Dinehart SM, Farberg AS: Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma. 20(6):763-770, 2019.
59. Nazarian RS, Farberg AS, Hashim PW, Goldenberg G: Nonsurgical hair restoration treatment. *Cutis*. 104(1):17-24, 2019.
60. Dubin DP, Farberg AS, Lin MJ, Khorasani H: Response to Commentary on Intralesional Deoxycholic Acid as a Neoadjuvant Treatment of a Large Lipoma. *Dermatol Surg*. 46(5):718-9, 2020.
61. Shamloul N, Hashim PW, Nia JJ, Farberg AS, Goldenberg G: The role of vitamins and supplements on skin appearance. *Cutis*. 104(4):220-224, 2019.
62. Lin MJ, Dubin DP, Farberg AS, Khorasani H, Kriegel DA: Methacrylate Polymer Powder Dressing for a Nasal Surgical Defect. *J Drugs Dermatol*. 18(12):1274-5, 2019.
63. Wysong A, Newman JG, Covington KR, Kurley SJ, Ibrahim SF, Farberg AS, Bar A, Cleaver NJ, Somani AK, Panther D, Brodland DG, Zitelli J, Toyohara J, Maher IA, Xia Y, Bibee K, Griego R, Rigel DS, Meldi Plasseraud K, Estrada S, Sholl LM, Johnson C, Cook RW, Schmults CD, Arron ST: Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 84(2):316-9, 2021.
64. Farberg AS, Hall MA, Douglas L, Covington KR, Kurley SJ, Cook RW, Dinehart SM: Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management. *Curr Med Res Opin*. 36(8):1301-7, 2020.

65. Dubin DP, Lin MJ, Leight HM, Farberg AS, Torbeck RL, Burton WB, Khorasani H: The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial. *J Am Acad Dermatol.* 83(5):1294-7, 2020.
66. Rogers Flattery CN, Rosen RF, Farberg AS, Dooyema JM, Hof PR, Sherwood CC, Walker LC, Preuss TM: Quantification of neurons in the hippocampal formation of chimpanzees: comparison to rhesus monkeys and humans. *Brain Struct Funct.* 225(8):2521-31, 2020.
67. Kwan KR, Kolansky Z, Abittan BJ, Farberg AS, Goldenberg G: Skin Tightening. *Cutis.* 106(3):134-7, 2020.
68. Estrada S, Shackelton J, Cleaver N, Depcik-Smith N, Cockerell C, Lencioni S, Martin H, Wilkinson J, Sholl LM, Berg M, Russell B, Zolochovska O, Covington K, Farberg AS, Goldberg M, Gerami P, Hosler G: Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions. *SKIN The Journal of Cutaneous Medicine.* 4(6): 506-22, 2020.
69. Farberg AS, Ahmed K, Bailey C, Russell B, Douglas K, Johnson C, Zolochovska O, Cook R, Goldberg M: A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists. *SKIN The Journal of Cutaneous Medicine.* 4(6):523-33, 2020.
70. Migden M, Farberg AS, Drummer R, Squittieri N, Hanke CW. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. *J Drugs Dermatol.* 20(2):156-65, 2021.
71. Nazarian RS, Farberg AS, Smith BL. Candida Esophagitis Associated with Adalimumab for Hidradenitis Suppurativa. *Cutis.* 107(3):E6-E7, 2021.
72. Farberg AS, Soleymani T, Ratner D. Bridging the Gap: Integrating Gene Expression Profiling into Clinical Practice. *J Drugs Dermatol.* 1;20(6):s4, 2021.
73. Newman JG, Hall MA, Kurley SJ, Cook RW, Farberg AS, Geiger JL, Koyfman SA. Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. *Head Neck.* 43(9):2822-2843, 2021.
74. Lewis K, Drummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of Sonidegib Following Dose Reduction and Treatment

Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial. *Dermatol Ther.* 11(6):2225-2234, 2021.

75. Ibrahim SF, Kasprzak JM, Hall MA, Fitzgerald AL, Siegel JJ, Kurley SJ, Covington KR, Goldberg MS, Farberg AS, Trotter SC, Reed K, Brodland DG, Koyfman SA, Somani AK, Arron ST, Wysong A. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. *Future Oncol.* 18(7):833-847, 2021.
76. Farberg AS, Fitzgerald AL, Ibrahim SF, Tolkachjov SN, Douglas LM, Kurley SJ, Arron ST. Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review. *Dermatol Ther.* 12(2):267-284, 2022.
77. Borman S, Wilkinson J, Meldi-Sholl L, Johnson C, Covington KR, Fitzgerald AL, Kurley SJ, Farberg AS, Goldberg MS, Monzon FA, Oelschlager K, Cook RW. Analytic validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. *Diagn Pathol.* 25;17(1):32, 2022.
78. Farberg AS, Marson JW, Glazer A, Litchman GH, Svoboda R, Winkelmann RR, Brownstone N, Rigel DS. Expert Consensus on the Use of Prognostic Gene Expression Profile Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group. *Dermatol Ther.* 12(4):807-823, 2022.
79. Brownstone N, Marson JW, Zakria D, Farberg AS, Rigel D. Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update. *Melanoma Res.* 32(5):379-383, 2022.
80. Hooper PB, Farberg AS, Fitzgerald AL, Siegel JJ, Rackley BB, Prasai A, Kurley SJ, Goldberg MS, Litchman GH. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. *Cancer Invest.* 40(10):911-922, 2022.
81. Farberg AS, Marson JW, Soleymani T. Advances in Photodynamic Therapy for the Treatment of Actinic Keratosis and Nonmelanoma Skin Cancer: A Narrative Review. *Dermatol Ther (Heidelb).* 2023 Mar;13(3):689-716.
82. Marks E, Jarell A, Ludzik J, Farberg AS, Rabinovitz HS, Phelps RG, Cockerell CJ, Witkowski A. A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms. *J Clin Aesthet Dermatol.* 2023 Apr;16(4):12-20.

83. Singh G, Tolkachjov SN, Farberg AS. Incorporation of the 40-Gene Expression Profile (40-GEP) Test to Improve Treatment Decisions in High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients: Case Series and Algorithm. *Clin Cosmet Investig Dermatol*. 2023 Apr 5;16:925-935.
84. Marks E, Jarell A, Ludzik J, Farberg AS, Rabinovitz HS, Phelps RG, Cockerell CJ, Witkowski A. A Physician's Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms. *J Clin Aesthet Dermatol*. 2023 Apr;16(4):12-20
85. Palomares SJ, Farberg AS. Nonulcerated Necrobiosis Lipoidica Successfully Treated with Tapinarof: A Case Report. *Clin Cosmet Investig Dermatol*. 2023 May 29;16:1373-1376.
86. Baldwin H, Farberg A, Frey C, Hartman C, Lain E, Meltzer R, Draelos Z. Unmet Needs in the Management of Acne Vulgaris: A Consensus Statement. *J Drugs Dermatol*. 2023 Jun 1;22(6):582-587.
87. Garg A, Noe MH, Anadkat MJ, Armstrong A, Bhutani T, Farberg A, Han G, Hawkes JE, Lebwohl M, Rekhtman S, Song EJ, Strunk A, Duffin KC. Development of the Generalized Pustular Psoriasis Clinical Assessment Tool. *J Am Acad Dermatol*. 2024 Jan;90(1):192-195.
88. Somani AK, Ibrahim SF, Tassavor M, Yoo J, Farberg AS. Use of the 40-gene Expression Profile (40-GEP) Test in Medicare-eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs. *J Clin Aesthet Dermatol*. 2024 Jan;17(1):41-44.
89. Bhutani T, Farberg AS. Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence. *Dermatol Ther (Heidelb)*. 2024 Feb;14(2):341-360.
90. Wysong A, Somani AK, Ibrahim SF, Cañueto J, Fitzgerald AL, Siegel JJ, Prasai A, Goldberg MS, Farberg AS, Regula C, Bar A, Kasprzak J, Brodland DG, Koefman SA, Arron ST. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. *Dermatol Ther (Heidelb)*. 2024 Mar 1.
91. Moody BR, Farberg AS, Somani AK, Taylor WA. Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell

- Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance. *Dermatol Ther (Heidelb)*. 2024 Apr;14(4):861-873.
92. Farberg AS, Palomares SJ, Nguyen TQ, Emesiani C, Meckfessel M. An Over-the-Counter Healing Ointment: Benefits in Dry Skin and Wound Healing. *J Drugs Dermatol*. 2024 May 1;23(5):360-365.
 93. Brownstone ND, Farberg AS, Litchman GH, Quick AP, Siegel JJ, Hurton LV, Goldberg MS, Lio PA. Improving systemic therapy selection for inflammatory skin diseases: A clinical need survey. *JAAD Int*. 2024 Apr 6;16:49-56.
 94. Witkowski A, Jarell AD, Ahmed KL, Siegel JJ, Russell BH, Rogers JH, Goldberg MS, Fernandes NF, Ludzik J, Farberg AS. A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management. *Melanoma Manag*. 2024 May 9;11(1):MMT68.

Books/Chapters:

1. Larin, Linda R., ed. Farberg, Aaron S: Inspired to Change: Improving Patient Care One story at a Time; “Dear Doctor.” Chicago: Health Administration Press, Nov 2013.
2. Farberg AS, Rigel DS: Screening, Diagnosis, and Prognosis of Skin Cancer. *Skin Cancer @ Point of Care*. Projects In Knowledge. Online [<http://skin-cancer.atpointofcare.com/beta/book/index.html#/2256.31/page/0>], 2016.
3. Farberg AS, Rigel DS: Lentigo Maligna. *Treatment of Skin Disease: Comprehensive Therapeutic Strategies 5th Edition*. Elsevier. 2017.
4. Farberg AS, Rigel DS: Non-Invasive Technologies for the Diagnosis of Skin Cancer. *Dermatologic Clinics*. Elsevier. Oct 2017.
5. Glazer AM, Farberg AS, Rigel DS: Surgical Approaches to Nonmelanoma Skin Cancer. *Dermatologic Surgery*. McGraw-Hill. 2018.
6. Farberg AS, Glazer AM, Ratner D: Aesthetic Surgical Concerns in Skin Cancer. *Cosmetic Dermatology*. Wolters Kluwer/Lippincott. In Press.

7. Farberg AS, Bernstein D, Vinelli G, Khorasani H: Rhytidectomy. *Evidence-Based Procedural Dermatology 2nd Ed.* Springer. In Press.

Abstracts and Editorials:

1. Farberg AS, Rosen RF, Long P, Gearing M, Klein W, Walker LC: Neuropathological analysis of posterior cingulate cortex in aging and Alzheimer's disease. Society for Neuroscience; San Diego, CA, Nov 2007.
2. Farberg AS, Rosen RF, Gearing M, Pare J, Walker LC: Fibrillar beta-amyloid in white matter of Alzheimer's disease brain. 12th International Conference on Alzheimer's Disease and Related Disorders; Chicago, IL, July 2008.
3. Farberg AS, Jing XL, Monson LA, Buchman SR: Vascular anatomic mapping of the rat mandible using microcomputed tomography. *J Plast Reconstr Surg.* 124(4S):103, 2009.
4. Farberg AS, Jing XL, Monson LA, Tchanque-Fossuo CN, Donneys A, Deshpande SS, Buchman SR: Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. American Association of Plastic Surgeons; San Antonio, TX, Mar 2010.
5. Farberg AS, Lin AM, Kuhn L, Flanders S, Kim CS: Dear doctor: a tool to facilitate patient-centered care and enhance communication. American Academy on Communication in Healthcare; Scottsdale, AZ, Oct 2010.
6. Farberg AS, Jing XL, Monson LA, Tchanque-Fossuo CN, Donneys A, Deshpande SS, Buchman SR: Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. *J Plast Reconstr Surg.* 125(6):S39, 2010.
7. Farberg AS, Lin AM, Kuhn L, Flanders S, Kim CS: Dear doctor: a tool to facilitate patient-centered care and enhance communication. *J Hosp Medicine.* 5(S1):88, 2010.
8. Farberg AS, Razdolsky ER; Jing XL, Zehtabzadeh AJ, Tchanque-Fossuo CN, Donneys A, Deshpande SS, Monson LA, Buchman SR: Deferoxamine Treatment Increases Osteocyte Count in Mandibular Distraction Osteogenesis. American Society of Plastic Surgeons; Toronto, Canada, Oct 2010.
9. Farberg AS, Lin AM, Kuhn L, Flanders S, Kim CS: Dear doctor: a tool to facilitate patient-centered care and enhance communication. Patient and Family Centered Care Conference; Ann Arbor, MI, Dec 2010.

10. Farberg AS, Agarwal S, Kidwell KM, Kozlow JH, Chung KC, Momoh AO: Immediate Reconstruction of the Radiated Breast: An Analysis of National Trends. American College of Surgeons Annual Meeting; San Francisco, CA, Oct 2014.
11. Farberg AS, Rigel DS: A comparison of current practice patterns of US dermatologists' vs published guidelines for the management of primary cutaneous melanoma. American Society for Dermatologic Surgery Annual Meeting; Chicago, IL, Oct 2015.
12. Ouyang H, Meyer K, Maltra P, Daly S, Farberg AS, Rigel DS: Realistic Sunscreen Durability – A Randomized, Double-Blinded, Controlled Clinical Study. *J Am Acad Dermatol.* 74(5)Suppl1:AB228, 2016.
13. Cook RW, Farberg AS, Glazer AM, Rigel DS: Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions. Society for Melanoma Research; Boston, MA, Nov 2016.
14. Williams JD, Maitra P, Atillasoy E, Wu M, Farberg AS, Rigel DS: Split-face, Double-blind Comparison of Sun Protection Factor 100+ and 50+ Sunscreen Under Actual-use Conditions: A Randomized Clinical Trial. American Academy of Dermatology Annual Meeting; Orlando, FL, Apr 2017.
15. Farberg AS, Glazer AM, Rigel DS: Comparison of Differing Survey Modalities in Assessing Dermatologists Perceptions and Opinions of Sunscreens. American Academy of Dermatology Annual Meeting; Orlando, FL, Apr 2017.
16. Farberg AS, Wysong A, Newman JG, Covington KR, Plasseraud KM, Cook RW, Schmults CD, Arron S: Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. American Society for Dermatologic Surgery Annual Meeting; Phoenix, AZ, Oct 2018.
17. Farberg AS, Prado G, Ederle AE, Shahriari S, Svoboda RM, Rigel DS: Factors Influencing Online Sunscreen Purchases: Impact of Consumer Preferences, Product Characteristics, and Unregulated Marketing Claims. Society for Phototherapy and Photoprotection Annual Meeting; Washington, D.C., Feb 2019.
18. Dubin DP, Lin MJ, Farberg AS, Khorasani H: Intralesional Deoxycholic Acid as Neoadjuvant Treatment of a Large Lipoma. American Academy of Dermatology Annual Meeting; Washington, D.C., Feb 2019.

19. Prado G, Svoboda RM, Glazer A, Farberg AS, Rigel DS: Factors Influencing Dermatology Rank List Preferences Among Successful Applicants. Atlantic Dermatological Conference; New York, NY, May 2019.
20. Farberg AS, Hall MA, Douglas L, Covington KR, Kurley SJ, Cook RW, Dinehart SD: Integrating the 40-Gene Expression Profile Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma. Winter Clinical Dermatology Conference; Kohala Coast, HI, Jan 2020.
21. 50+ abstracts needing to be updated.

Presentations:

1. American Society of Plastic Surgeons. Vascular anatomic mapping of the rat mandible using microcomputed tomography. Seattle, WA, Oct 2009.
2. American Association of Plastic Surgeons. Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. San Antonio, TX, Mar 2010.
3. Society for Hospital Medicine. Dear doctor: a tool to facilitate patient-centered care and enhance communication. Washington, DC, Mar 2010.
4. Plastic Surgery Research Council. Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. San Francisco, CA, May 2010.
5. American Academy on Communication in Healthcare. Dear doctor: a tool to facilitate patient-centered care and enhance communication. Scottsdale, AZ, Oct 2010.
6. American Society of Plastic Surgeons. Deferoxamine Treatment Increases Osteocyte Count in Mandibular Distraction Osteogenesis. Toronto, Canada, Oct 2010.
7. Moses Gunn Research Conference. Deferoxamine Treatment Restores Vascularity in Irradiated Mandibular Distraction Osteogenesis. Ann Arbor, MI, June 2010.
8. Patient and Family Centered Care Conference. Dear doctor: a tool to facilitate patient-centered care and enhance communication. Ann Arbor, MI, Dec 2010.

9. Winter Clinical Dermatology Conference. Sun Protection by Beach Umbrella vs Sunscreen with a High Sun Protection Factor: A Randomized Clinical Trial. Kauai, HI, Jan 2016.
10. Dermatologic Society of Greater New York. Split-face, Double-blind Comparison of Sun Protection Factor 100+ and 50+ Sunscreen Under Actual-use Conditions: A Randomized Clinical Trial. New York, NY, Jan 2017.
11. Winter Clinical Dermatology Conference. Split-face, Double-blind Comparison of Sun Protection Factor 100+ and 50+ Sunscreen Under Actual-use Conditions: A Randomized Clinical Trial. Kona, HI, Jan 2017.
12. Graduate Medical Education Research Day, Icahn School of Medicine at Mount Sinai. Split-face, Double-blind Comparison of Sun Protection Factor 100+ and 50+ Sunscreen Under Actual-use Conditions: A Randomized Clinical Trial. New York, NY, June 2017.
13. Winter Clinical Dermatology Conference. Realistic Sunscreen Durability: A Randomized, Double-blinded, Controlled Clinical Study. Maui, HI, Jan 2018.
14. American Society for Dermatologic Surgery Annual Meeting. Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. Phoenix, AZ, Oct 2018.
15. Dermatologic Society of Greater New York. In Vitro Evaluation of Preinjection Aspiration for Hyaluronic Fillers as Safety Checkpoint. New York, NY, Jan 2019.
16. Winter Clinical Dermatology Conference. In Vitro Evaluation of Preinjection Aspiration for Hyaluronic Fillers as Safety Checkpoint. Kauai, HI, Jan 2019.
17. American Academy of Dermatology, Annual Meeting. Update on Hedgehog Inhibitors (Faculty). Washington, D.C., Mar 2019.
18. Non-Invasive Diagnostic Innovations in Skin, Spring Symposium. Psoriasis Biologics Bootcamp (Faculty). New York, NY, May 2019.
19. New York Academy of Medicine, Dermatology Resident's Night. Development of a multi-gene expression profile for recurrence risk prediction in cutaneous squamous cell carcinoma. New York, NY, Jun 2019.

20. Fall Clinical Dermatology Conference. Regenerative Medicine: How to Integrate It into Practice. Las Vegas, NV, Oct 2019.
21. Winter Clinical Dermatology Conference. Alpha Project Session Organizer and Lead. Virtual, Jan 2021.
22. Board Immersion Course. Tips for Passing the Dermatology Board Exam. Las Vegas, NV, Mar 2021.
23. American Academy of Dermatology, Summer Meeting. Update on Psoriatic Arthritis (Faculty). Tampa, FL, Aug 2021.
24. Galderma National Sales Meeting. A Day in the Life of a Dermatologist. Dallas, TX, Jan 2022.
25. Fort Worth Dermatology Society Meeting. Update in Precision Medicine for Skin Cancer. Fort Worth, TX, Mar 2022.
26. Real World for Dermatology Conference. Evolving Your Career in Dermatology. Las Vegas, NV, Apr 2022.
27. American Academy of Dermatology, Summer Meeting. Advanced Diagnostics, Molecular Testing for Melanoma. Vancouver, BC, Canada, Jul 2022.
28. Dermajal. Update on Sensitive Skincare. Guadalajara, Mexico, Jul 2022.
29. Dermajal. The use of trifarotene in acne. Guadalajara, Mexico, Jul 2022.
30. South Beach Symposium. Tips and Tricks for Hedge Hog Inhibitors. Miami, FL, Aug 2022.
31. South Beach Symposium. Update in Precision Medicine for Skin Cancer. Miami, FL, Aug 2022.
32. Fall Clinical Dermatology Conference. What's New in Precision Medicine for Dermatology. Las Vegas, NV, Oct 2022.
33. Fall Clinical Dermatology Conference. 20 Tips in 20 minutes. Las Vegas, NV, Oct 2022.
34. Fall Clinical Dermatology Conference. Tips and Tricks for Early Career Dermatologists. Las Vegas, NV, Oct 2022.
35. Derm Scholar Conference. Overview of Clinical Trials in Dermatology. Parsippany, NJ, Nov 2022.

36. Winter Clinical Dermatology Conference. Inflammatory Disease, Program Moderator. Kona, HI, Jan 2023.
37. Winter Clinical Dermatology Conference. Inflammatory Disease Management: How Do I Switch Biologics. Kona, HI, Jan 2023.
38. South Beach Symposium. Tips and Tricks for Hedge Hog Inhibitors. Miami, FL, Aug 2023.
39. South Beach Symposium. Update in Precision Medicine for Skin Cancer. Miami, FL, Aug 2023.
40. Winter Clinical Dermatology Conference. Early Career Dermatology Tips & Tricks, Moderator. Miami, FL, Mar 2023.
41. Winter Clinical Dermatology Conference. Applying Genomics and Precision Medicine to Your Patient Management. Miami, FL, Mar 2023.
42. Winter Clinical Dermatology Conference. My Top 10 Pearls and Pitfalls from My First Five Years in Practice. Miami, FL, Mar 2023.
43. American Academy of Dermatology, Annual Meeting. Update on Staging and Prognosis in Melanoma. New Orleans, LA, Mar 2023.
44. Real World for Dermatology Conference. Evolving Your Career in Dermatology. Las Vegas, NV, Apr 2023.
45. World Congress of Dermatology. Expert Meeting – Type 2 Inflammatory Skin Diseases. Singapore, Singapore, Jul 2023.
46. World Congress of Dermatology. Staging and Prognosis of Melanoma. Singapore, Singapore, Jul 2023.
47. Fall Clinical Dermatology Conference. Early Career Dermatology Initiative. Las Vegas, NV, Oct 2023.
48. OhioHealth Grand Rounds. Update on Melanoma and Cutaneous Squamous Cell Carcinoma. Columbus, OH, Dec 2023.
49. Winter Clinical Dermatology Conference. Precision Medicine for Skin Cancer. Oahu, HI, Jan 2024.
50. South Beach Symposium. Update in Precision Medicine for Skin Cancer. Miami, FL, Aug 2024.

51. Winter Clinical Dermatology Conference. Diagnostic Techniques to Improve Patient Care. Miami, FL, Mar 2024.
52. Winter Clinical Dermatology Conference. Early Career Dermatology Initiative. Miami, FL, Mar 2024.
53. Winter Clinical Dermatology Conference. Diagnostic Techniques to Improve Patient Care. Miami, FL, Mar 2024.
54. Winter Clinical Dermatology Conference. Early Career Dermatology Initiative. Miami, FL, Mar 2024.
55. American Academy of Dermatology, Annual Meeting. Billing and Coding: Local Coverage Determinations. San Diego, Mar 2024.
56. Update from the American Academy of Dermatology, Inflammatory Disease. TalkMED Reimagining Medicine: Shanghai, Xi'an, Guangzhou, Zhuhai, Beijing, China, Mar 2024
57. How to Design Clinical Trials. TalkMED Reimagining Medicine: Shanghai, Xi'an, Guangzhou, Zhuhai, Beijing, China, Mar 2024
58. Pioneers Live Annual Meeting. Treatment of Chronic Generalized Pustular Psoriasis. Ingelheim, Germany, Apr 2024